Short Interest in Carisma Therapeutics, Inc. (NASDAQ:CARM) Decreases By 13.7%

Carisma Therapeutics, Inc. (NASDAQ:CARMGet Free Report) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 1,570,000 shares, a drop of 13.7% from the April 30th total of 1,820,000 shares. Currently, 7.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 174,500 shares, the days-to-cover ratio is presently 9.0 days.

Institutional Trading of Carisma Therapeutics

A hedge fund recently raised its stake in Carisma Therapeutics stock. Vanguard Group Inc. grew its stake in shares of Carisma Therapeutics, Inc. (NASDAQ:CARMFree Report) by 0.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,579,961 shares of the company’s stock after purchasing an additional 11,200 shares during the quarter. Vanguard Group Inc. owned approximately 3.80% of Carisma Therapeutics worth $3,587,000 as of its most recent SEC filing. Institutional investors own 44.27% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. BTIG Research assumed coverage on Carisma Therapeutics in a report on Thursday, April 11th. They set a “buy” rating and a $6.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Carisma Therapeutics in a research report on Friday, May 17th.

Get Our Latest Stock Report on CARM

Carisma Therapeutics Trading Up 1.5 %

NASDAQ:CARM opened at $1.33 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.64 and a current ratio of 4.64. Carisma Therapeutics has a one year low of $1.24 and a one year high of $9.77. The business’s 50-day simple moving average is $1.69 and its 200 day simple moving average is $2.22. The stock has a market cap of $55.25 million, a price-to-earnings ratio of -0.67 and a beta of 1.00.

Carisma Therapeutics (NASDAQ:CARMGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.09). Carisma Therapeutics had a negative return on equity of 215.95% and a negative net margin of 538.81%. The business had revenue of $3.40 million during the quarter, compared to analyst estimates of $3.90 million. As a group, sell-side analysts predict that Carisma Therapeutics will post -1.72 earnings per share for the current fiscal year.

About Carisma Therapeutics

(Get Free Report)

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.

See Also

Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with's FREE daily email newsletter.